Close Menu

NEW YORK (GenomeWeb) – Guardant Health this week said that it has made new improvements to its Guardant360 comprehensive liquid biopsy test.

Although it has not yet made public the validation data supporting these numbers, the company now lists a reportable range for its assay down to 0.04 percent mutant allele fraction for SNPs and 0.02 MAF for indels.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.